• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    ALX Oncology Holdings Inc. - Common Stock (NQ:ALXO)

    1.780 -0.020 (-1.11%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 858,751
    Open 1.760
    Bid (Size) 1.780 (800)
    Ask (Size) 1.830 (100)
    Prev. Close 1.800
    Today's Range 1.690 - 1.825
    52wk Range 0.4040 - 2.660
    Shares Outstanding 40,869,135
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    ALX Oncology (ALXO) Q1 2026 Earnings Transcript ↗
    ALX Oncology (ALXO) Q1 2026 Earnings Transcript 
    Via The Motley Fool
    News headline image
    ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York
    From ALX Oncology
    Via GlobeNewswire

    Performance

    YTD
    +54.8%
    +54.8%
    1 Month
    -5.3%
    -5.3%
    3 Month
    -16.0%
    -16.0%
    6 Month
    +34.8%
    +34.8%
    1 Year
    +218.6%
    +218.6%

    More News

    Read More
    News headline image
    ALX Oncology Q1 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    ALX Oncology Holdings Inc (NASDAQ:ALXO) Beats Q1 Estimates and Unveils Promising Breast Cancer Data ↗
    Via Chartmill
    ALX Oncology (NASDAQ:ALXO) Extends Cash Runway to 2028, Refines Evorpacept Strategy After Q4 Earnings ↗
    Via Chartmill
    News headline image
    ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
    From ALX Oncology
    Via GlobeNewswire
    News headline image
    ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression
    From ALX Oncology
    Via GlobeNewswire
    News headline image
    ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026
    From ALX Oncology
    Via GlobeNewswire
    News headline image
    ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer
    From ALX Oncology
    Via GlobeNewswire
    News headline image
    ALX Oncology (ALXO) Q4 2025 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
    From ALX Oncology
    Via GlobeNewswire
    News headline image
    ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026
    From ALX Oncology
    Via GlobeNewswire
    News headline image
    ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026
    From ALX Oncology
    Via GlobeNewswire
    News headline image
    ALX Oncology Announces Pricing of Underwritten Offering
    From ALX Oncology
    Via GlobeNewswire
    News headline image
    New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer
    From ALX Oncology
    Via GlobeNewswire
    News headline image
    ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From ALX Oncology
    Via GlobeNewswire
    News headline image
    ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004
    From ALX Oncology
    Via GlobeNewswire
    News headline image
    ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
    From ALX Oncology
    Via GlobeNewswire
    News headline image
    Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
    Via FinancialNewsMedia
    News headline image
    Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
    From FN Media Group LLC
    Via GlobeNewswire
    News headline image
    ALX Oncology to Present at Upcoming Investor Conferences
    From ALX Oncology
    Via GlobeNewswire
    News headline image
    ALX Oncology Holdings Inc (NASDAQ:ALXO) Reports Wider-Than-Expected Q3 2025 Loss Amid Promising Clinical Data ↗
    Via Chartmill
    News headline image
    ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update
    From ALX Oncology
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For November 7, 2025 ↗
    Via Benzinga
    News headline image
    Examining the Future: ALX Oncology Holdings's Earnings Outlook ↗
    Via Benzinga

    Frequently Asked Questions

    Is ALX Oncology Holdings Inc. - Common Stock publicly traded?
    Yes, ALX Oncology Holdings Inc. - Common Stock is publicly traded.
    What exchange does ALX Oncology Holdings Inc. - Common Stock trade on?
    ALX Oncology Holdings Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for ALX Oncology Holdings Inc. - Common Stock?
    The ticker symbol for ALX Oncology Holdings Inc. - Common Stock is ALXO on the Nasdaq Stock Market
    What is the current price of ALX Oncology Holdings Inc. - Common Stock?
    The current price of ALX Oncology Holdings Inc. - Common Stock is 1.780
    When was ALX Oncology Holdings Inc. - Common Stock last traded?
    The last trade of ALX Oncology Holdings Inc. - Common Stock was at 06/02/26 04:00 PM ET
    What is the market capitalization of ALX Oncology Holdings Inc. - Common Stock?
    The market capitalization of ALX Oncology Holdings Inc. - Common Stock is 72.75M
    How many shares of ALX Oncology Holdings Inc. - Common Stock are outstanding?
    ALX Oncology Holdings Inc. - Common Stock has 73M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.